Cargando…

Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data

BACKGROUND: Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by deficiency in acid beta-glucosidase. GD exhibits a wide clinical spectrum of disease severity with an unpredictable natural course. Plasma chitotriosidase activity and CC chemokine ligand 18 (CCL18) have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raskovalova, Tatiana, Deegan, Patrick B., Yang, Ruby, Pavlova, Elena, Stirnemann, Jérome, Labarère, José, Zimran, Ari, Mistry, Pramod K., Berger, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397740/ https://www.ncbi.nlm.nih.gov/pubmed/28427477 http://dx.doi.org/10.1186/s13643-017-0483-x

Ejemplares similares

Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data
por: Raskovalova, Tatiana, et al.
Publicado: (2020)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Chitotriosidase Activity and Gene Polymorphism in Iranian Patients with Gaucher Disease and Sibling Carriers
por: MOZAFARI, Hadi, et al.
Publicado: (2016)

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Dental profile of patients with Gaucher disease
por: Fischman, Stuart L, et al.
Publicado: (2003)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients—A Qualitative and Quantitative Approach
por: Szymańska-Rożek, Paulina, et al.
Publicado: (2023)

Simultaneous Bilateral Femoral Osteonecrosis in Gaucher Disease
por: Cohen, Daniel, et al.
Publicado: (2023)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Type 3 Gaucher disease, diagnostic in adulthood
por: Detollenaere, Charles, et al.
Publicado: (2017)

Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: a prospective observational study
por: De Castro-Orós, Isabel, et al.
Publicado: (2017)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2018)

Increased chitotriosidase activity in plasma of patients with type 2 diabetes
por: Żurawska-Płaksej, Ewa, et al.
Publicado: (2016)

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
por: Mistry, Pramod K, et al.
Publicado: (2009)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Immunomodulatory Effects of Chitotriosidase Enzyme
por: Elmonem, Mohamed A., et al.
Publicado: (2016)

Chitotriosidase as a biomarker for gangliosidoses
por: Kim, Sarah, et al.
Publicado: (2021)

Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease
por: Lebel, Ehud, et al.
Publicado: (2009)

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy
por: Serratrice, Christine, et al.
Publicado: (2016)

Achievement of Therapeutic Goals with Low-Dose Imiglucerase in Gaucher Disease: A Single-Center Experience
por: Tukan, Irina, et al.
Publicado: (2013)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

Bone events and evolution of biologic markers in Gaucher disease before and during treatment
por: Stirnemann, Jérôme, et al.
Publicado: (2010)

Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy
por: Orchard, Paul J, et al.
Publicado: (2011)

The relationship between chitotriosidase activity and tuberculosis
por: CHEN, M., et al.
Publicado: (2015)

Human Chitotriosidase Is an Endo-Processive Enzyme
por: Kuusk, Silja, et al.
Publicado: (2017)

Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry
por: Nguyen, Yann, et al.
Publicado: (2020)

A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
por: Stirnemann, Jérôme, et al.
Publicado: (2017)

Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2015)

The mutation spectrum in Indian patients with Gaucher disease
por: Bisariya, Vartika, et al.
Publicado: (2011)

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites in Gaucher Disease
por: Adhyaru, Kunal, et al.
Publicado: (2022)

Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease
por: Dinur, Tama, et al.
Publicado: (2020)

Brain-Derived Neurotrophic Factor (BDNF) Is Associated with Platelet Activity and Bleeding Tendency in Patients with Gaucher Disease
por: Azoulay, David, et al.
Publicado: (2022)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Imiglucerase in the treatment of Gaucher disease: a history and perspective
por: Deegan, Patrick B, et al.
Publicado: (2012)

Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease
por: Charkhand, Behshad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mp6qpopsf7d9sgu1qub2452v90